<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572754</url>
  </required_header>
  <id_info>
    <org_study_id>Drycirc Vz10d</org_study_id>
    <secondary_id>NEB002180</secondary_id>
    <nct_id>NCT00572754</nct_id>
  </id_info>
  <brief_title>Phase II Trial to Evaluate the Safety and Efficacy of the Dry Circumcision Method</brief_title>
  <official_title>Phase II Trial to Evaluate the Safety and Efficacy of the Dry Circumcision</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Progressus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Progressus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical investigation is to provide the first and preliminary clinical
      data to study the safety and efficacy of male circumcision where the dry circumcision method
      is employed.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">March 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The operative and short-term post-operative safety rates</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mobibidity and mortality The length of the residual foreskin.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Circumcision</condition>
  <condition>Male</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Circumcision</intervention_name>
    <description>Circumcision by tying a ligature around the foreskin.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male subjects, aged 21 years or above at the point of screening for participation.

          2. Subjects who are able to give voluntary, written informed consent to participate in
             this clinical investigation and from whom consent has been obtained.

          3. Subjects who, in the opinion of the clinical investigator, are able to understand this
             clinical investigation co-operate with the investigational procedures and are willing
             to return to the clinical centre for all the required post-treatment follow-ups.

          4. Subjects willing to be circumcised for cultural reasons.

          5. Subjects living in the site's area.

          6. Subjects who can be easily contacted by telephone.

          7. Subjects who can correctly speak and correctly read English.

        Exclusion Criteria:

          1. Subjects who, in the opinion of the investigator, have an existing condition that
             would compromise their participation and follow-up in this study.

          2. Subjects who are circumcised (i.e. subjects with a foreskin unable to cover the entire
             glans without pulling on the foreskin).

          3. Subjects with a disease which is an indication for circumcision: phimosis,
             paraphimosis, warts under the prepuce, torn or tight frenulum.

          4. Subjects who are known drug or alcohol abusers or with psychological disorders that
             could affect follow-up care or treatment outcomes.

          5. Subjects who have participated in a clinical study with an investigational product in
             the last 6 months.

          6. Subjects who have an abnormal penile anatomy.

          7. Subjects who are currently involved in any injury litigation claims.

          8. Subjects who have penile diseases or lesions.

          9. Subjects who have clinical symptoms of sexually transmitted infections.

         10. Subjects with opportunistic infections.

         11. Subjects with known diabetes, known allergy to local anaesthesia or with known
             abnormal blood coagulation.

         12. Subjects whose penile circumference is higher (&gt;3mm) or lower (&lt;3mm) than the
             available circumcision tubes.

         13. Subjects with a thick foreskin (difference between the diameter of covered glans and
             uncovered glans &gt; 5mm).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertran Auvert, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UVSQ-INSERM-France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kasonde Bowa, MD</last_name>
    <phone>260 97 84 93 0</phone>
    <email>kbowa@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Teaching Hospital</name>
      <address>
        <city>Lusaka</city>
        <country>Zambia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasonde Bowa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kasonde Bowa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Zambia</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <last_update_submitted>December 12, 2007</last_update_submitted>
  <last_update_submitted_qc>December 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2007</last_update_posted>
  <responsible_party>
    <name_title>Bertran Auvert</name_title>
    <organization>University of Versailles (France)</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

